Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 191 |
| INN | Livmoniplimab |
| Status | Clinical |
| Drug code(s) | ABBV-151, ARGX-115, PR-1762844 |
| Brand name | None |
| mAb sequence source | mAb chimeric/humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG4 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Camelid-derived; SIMPLE Antibody |
| Target(s) | GARP/TGF beta complex |
| Indications of clinical studies | NSCLC, Hepatocellular Carcinoma, Solid tumors |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Phase 2/3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | February 21, 2019 |
| Start of Phase 2 | |
| Start of Phase 3 | January 15, 2024 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | argenx |
| Licensee/Partner | Eli Lilly and Company |
| Comments about company or candidate | NCT06236438 Phase 2/3 in NSCLC to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab started in April 2024. NCT06109272 Phase 2/3 in Hepatocellular Carcinoma in combination with budigalimab started in January 2024. NCT05822752 Phase 2 in hepatocellular carcinoma started in Aug 2023. NCT03821935 Phase 1 study started in Feb 2019 recruiting as of last update in Dec 2022. August 2018: argenx announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115, an antibody targeting the novel immuno-oncology target glycoprotein A repetitions predominant (GARP). April 2017: arGen-X recd. $10 million for preclinical milestone AbbVie Inc. acquired an exclusive option from argenx N.V. to license ARGX-115, a preclinical mAb against leucine-rich repeat containing 32 (LRRC32; GARP), to treat cancer. argenx will be responsible for R&D through IND-enabling studies, after which AbbVie may exercise the option. Licensed from de Duve Institute/Uni Catholique de Louvain; discovery using SIMPLE Antibody platform. GARP is a check-point inhibitor |
| Full address of company | 1101 EB Amsterdam, Netherlands Europe Netherlands https://www.argenx.com/contact-us |
Immune checkpoint target. ABBV-151 is a monoclonal antibody (mAb) that binds to the GARP-TGFβ1 complex and blocks TGFβ1 release. Glycoprotein A repetitions predominant (GARP), also known as Leucine-rich repeat containing 32 (LRRC32). Hinge-stabilized
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |